Claims for Patent: 9,187,496

Summary for Patent: 9,187,496

Title:	5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
Abstract:	Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. ##STR00001##
Inventor(s):	Dousson; Cyril B. (Canet, FR), Dukhan; David (Saint Gely du Fesc, FR), Parsy; Christophe Claude (Jacou, FR), Pierra; Claire (Montarnaud, FR), Alexandre; Francois-Rene (Montpellier, FR), Brandt; Guillaume (Montpellier, FR), Da Costa; Daniel (Saint Jean de Vedas, FR), Rahali; Houcine (Saint Laurent des Arbres, FR), Paparin; Jean-Laurent (Vendemian, FR), Derock; Michel (Grabels, FR), Convard; Thierry (Sathonay-Camp, FR), Surleraux; Dominique (Wauthier-Braine, BE)
Assignee:	Idenix Pharmaceuticals LLC (Cambridge, MA)
Application Number:	13/675,787
Patent Claims:	1. A method for treating or preventing an HCV infection in a human patient, which comprises administering to the patient a compound of Formula IC: ##STR00388## or a single enantiomer, a racemic mixture, a mixture of diastereomers, or a pharmaceutically acceptable salt, or solvate thereof; wherein: each R.sup.1 and R.sup.2 is independently (a) hydrogen; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) --C(O)R.sup.1a, --C(O)CH(NR.sup.1bR.sup.1c)R.sup.1a, --C(O)CH(N(R.sup.1c)C(O)R.sup.1b)R.sup.1a, --C(O)CH(N(R.sup.1c)C(O)OR.sup.1b)R.sup.1a, --C(O)CH(N(R.sup.1c)C(O)NR.sup.1bR.sup.1d)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1bR.sup.1c, --C(NR.sup.1a)NR.sup.1bR.sup.1c, --P(O)(OR.sup.1a)R.sup.1d, --CH.sub.2P(O)(OR.sup.1a)R.sup.1d, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --S(O)NR.sup.1bR.sup.1c, or --S(O).sub.2NR.sup.1bR.sup.1c; each R.sup.3a is independently hydrogen or R.sup.3; each R.sup.3, R.sup.5, and R.sup.6 is independently (a) cyano, halo, or nitro; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1bR.sup.1c, --C(NR.sup.1a)NR.sup.1bR.sup.1c, --OR.sup.1a, --OC(O)R.sup.1a, --OC(O)OR.sup.1a, --OC(O)NR.sup.1bR.sup.1c, --OC(.dbd.NR.sup.1a)NR.sup.1bR.sup.1c, --OS(O)R.sup.1a, --OS(O).sub.2R.sup.1a, --OS(O)NR.sup.1bR.sup.1c, --OS(O).sub.2NR.sup.1bR.sup.1c, --NR.sup.1bR.sup.1c, --NR.sup.1aC(O)R.sup.1d, --NR.sup.1aC(O)OR.sup.1d, --NR.sup.1aC(O)NR.sup.1bR.sup.1c, --NR.sup.1aC(.dbd.NR.sup.1d)NR.sup.1bR.sup.1c, --NR.sup.1aS(O)R.sup.1d, --NR.sup.1aS(O).sub.2R.sup.1d, --NR.sup.1aS(O)NR.sup.1bR.sup.1c, --NR.sup.1aS(O).sub.2NR.sup.1bR.sup.1c, --SR.sup.1a, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --S(O)NR.sup.1bR.sup.1c, or --S(O).sub.2NR.sup.1bR.sup.1c; or two R.sup.5 or two R.sup.6 that are attached to the same ring are linked together to form a bond, --O--, --NR.sup.7--, --S--, C.sub.1-6 alkylene, C.sub.1-6 heteroalkylene, C.sub.2-6 alkenylene, or C.sub.2-6 heteroalkenylene; L.sup.1 and L.sup.2 are each independently selected from: a bond, ##STR00389## wherein each moiety is optionally substituted with one, two, three, or four R.sup.3; the star (*) on each moiety represents the point of attachment thought which the moiety is connected to ##STR00390## and the zigzag line () on each moiety represents the point of attachment through which the moiety is connected to ##STR00391## and wherein T.sup.3 is a bond, C, N, O, S, CR.sup.3a, or NR.sup.3a; U.sup.3, V.sup.3, W.sup.3, and X.sup.3 are each independently C, N, O, S, CR.sup.3a, or NR.sup.3a; and Y.sup.3 is C or N; each Z.sup.1 and Z.sup.2 is independently a bond; each R.sup.7 is independently (a) hydrogen; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1bR.sup.1c, --C(NR.sup.1a)NR.sup.1bR.sup.1c, --OR.sup.1a, --OC(O)R.sup.1a, --OC(O)OR.sup.1a, --OC(O)NR.sup.1bR.sup.1c, --OC(.dbd.NR.sup.1a)NR.sup.1bR.sup.1c, --OS(O)R.sup.1a, --OS(O).sub.2R.sup.1a, --OS(O)NR.sup.1bR.sup.1c,--OS(O).sub.2NR.sup.1bR.sup.1c,--NR.sup.1bR.sup.- 1c, --NR.sup.1aC(O)R.sup.1d, --NR.sup.1aC(O)OR.sup.1d, --NR.sup.1aC(O)NR.sup.1bR.sup.1c,--NR.sup.1aC(.dbd.NR.sup.1d)NR.sup.1bR.s- up.1c, --NR.sup.1aS(O)R.sup.1d, --NR.sup.1aS(O).sub.2R.sup.1d, --NR.sup.1aS(O)NR.sup.1bR.sup.1c,--NR.sup.1aS(O).sub.2NR.sup.1bR.sup.1c, --P(O)(OR.sup.1a)R.sup.1d, --CH.sub.2P(O)(OR.sup.1a)R.sup.1d, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --S(O)NR.sup.1bR.sup.1c, or --S(O).sub.2NR.sup.1bR.sup.1c; each R.sup.1a, R.sup.1b, R.sup.1c, and R.sup.1d is independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or R.sup.1a and R.sup.1c together with the C and N atoms to which they are attached form heterocyclyl; or R.sup.1b and R.sup.1c together with the N atom to which they are attached form heterocyclyl; each n and p is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7; each q and r is independently an integer of 1, 2, 3, or 4; wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more substituents Q, where each Q is independently selected from (a) cyano, halo, or nitro; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one or more substituents Q.sup.a; or (c) --C(O)R.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.bR.sup.c, --C(NR.sup.a)NR.sup.bR.sup.c, --OR.sup.a, --OC(O)R.sup.a, --OC(O)OR.sup.a, --OC(O)NR.sup.bR.sup.c, --OC(.dbd.NR.sup.a)NR.sup.bR.sup.c, --OS(O)R.sup.a, --OS(O).sub.2R.sup.a, --OS(O)NR.sup.bR.sup.c, --OS(O).sub.2NR.sup.bR.sup.c, --NR.sup.bR.sup.c, --NR.sup.aC(O)R.sup.d, --NR.sup.aC(O)OR.sup.d, --NR.sup.aC(O)NR.sup.bR.sup.c, --NR.sup.aC(.dbd.NR.sup.d)NR.sup.bR.sup.c, --NR.sup.aS(O)R.sup.d, --NR.sup.aS(O).sub.2R.sup.d, --NR.sup.aS(O)NR.sup.bR.sup.c, --NR.sup.aS(O).sub.2NR.sup.bR.sup.c, --SR.sup.a, --S(O)R.sup.a, --S(O).sub.2R.sup.a, --S(O)NR.sup.bR.sup.c, or --S(O).sub.2NR.sup.bR.sup.c, wherein each R.sup.a, R.sup.b, R.sup.c, and R.sup.d is independently (i) hydrogen; (ii) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q.sup.a; or (iii) R.sup.b and R.sup.c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Q.sup.a; wherein each Q.sup.a is independently (a) cyano, halo, and nitro; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) --C(O)R.sup.e, --C(O)OR.sup.e, --C(O)NR.sup.fR.sup.g, --C(NR.sup.e)NR.sup.fR.sup.g, --OR.sup.e, --OC(O)R.sup.e, --OC(O)OR.sup.e, --OC(O)NR.sup.fR.sup.g, --OC(.dbd.NR.sup.e)NR.sup.fR.sup.g, --OS(O)R.sup.e, --OS(O).sub.2R.sup.e, --OS(O)NR.sup.fR.sup.g, --OS(O).sub.2NR.sup.fR.sup.g, --NR.sup.fR.sup.g, --NR.sup.eC(O)R.sup.h, --NR.sup.eC(O)OR.sup.f, --NR.sup.eC(O)NR.sup.fR.sup.g, --NR.sup.eC(.dbd.NR.sup.h)NR.sup.fR.sup.g, --NR.sup.eS(O)R.sup.h, --NR.sup.eS(O).sub.2R.sup.h, --NR.sup.eS(O)NR.sup.fR.sup.g, --NR.sup.eS(O).sub.2NR.sup.fR.sup.g, --SR.sup.e, --S(O)R.sup.e, --S(O).sub.2R.sup.e, --S(O)NR.sup.fR.sup.g, or --S(O).sub.2NR.sup.fR.sup.g; wherein each R.sup.e, R.sup.f, R.sup.g, and R.sup.h is independently (i) hydrogen; (ii) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R.sup.f and R.sup.g together with the N atom to which they are attached form heterocyclyl. 2. The method of claim 1, wherein the compound, or the single enantiomer, rademic mixture, or mixture of diastereomers therof, has the structure of Formula ICa: ##STR00392## 3. The method of claim 1, wherein the compound, or the single enantiomer, rademic mixture, or mixture of diastereomers therof, has the structure of Formula ICb: ##STR00393## wherein each R.sup.1e is independently (a) hydrogen; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q; or (c) --C(O)R.sup.1b, --C(O)OR.sup.1b, or --C(O)NR.sup.1bR.sup.1d. 4. The method of claim 1, wherein the compound, or the single enantiomer, racemic mixture, or mixture of diastereomers thereof, has the structure of Formula ICc: ##STR00394## wherein each R.sup.1e is independently (a) hydrogen; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q; or (c) --C(O)R.sup.1b, --C(O)OR.sup.1b, or --C(O)NR.sup.1bR.sup.1d. 5. The method of claim 1, wherein the compound, or the single enantiomer, racemic mixture, or mixture of diastereomers thereof, has the structure of Formula ICd: ##STR00395## wherein each R.sup.1e is independently (a) hydrogen; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q; or (c) --C(O)R.sup.1b, --C(O)OR.sup.1b, or --C(O)NR.sup.1bR.sup.1d. 6. The method of claim 1, wherein L.sup.1 and L.sup.2 are each independently: a bond, ##STR00396## wherein each moiety is optionally substituted with one, two, three, or four R.sup.3; the star (*) on each moiety represents the point of attachment through which the moiety is connected to ##STR00397## and the zigzag line () on each moiety represents the point of attachment through which the moiety is connected to ##STR00398## 7. The method of claim 6, wherein L.sup.1 and L.sup.2 are each independently: a bond, ##STR00399## ##STR00400## wherein each moiety is optionally substituted with one, two, three, or four R.sup.3. 8. The method of claim 1, wherein the compound, or the single enantiomer, racemic mixture, or mixture of diastereomers thereof, has the structure of Formula IIC: ##STR00401## 9. The method of claim 2, wherein the compound, or the single enantiomer, racemic mixture, or mixture of diastereomers thereof, has the structure of Formula IICa: ##STR00402## 10. The method of claim 3, wherein the compound, or the single enantiomer, racemic mixture, or mixture of diastereomers thereof, has the structure of Formula IICb: ##STR00403## 11. The method of claim 4, wherein the compound, or the single enantiomer, racemic mixture, or mixture of diastereomers thereof, has the structure of Formula IICc: ##STR00404## 12. The method of claim 5, wherein the compound, or the single enantiomer, racemic mixture, or mixture of diastereomers thereof, has the structure of Formula IICd: ##STR00405## 13. The method of claim 1, wherein R.sup.1 is --C(O)R.sup.1a, --C(O)CH(NR.sup.1bR.sup.1c)R.sup.1a, --C(O)CH[N(C(O)R.sup.1b)R.sup.1c]R.sup.1a, --C(O)CH[N(C(O)OR.sup.1b)R.sup.1c]R.sup.1a, or --C(O)CH[N(C(O)NR.sup.1dR.sup.1b)R.sup.1c]R.sup.1a. 14. The method of claim 13, wherein R.sup.1 is --C(O)CH[N(C(O)OR.sup.1b)R.sup.1c]R.sup.1a. 15. The method of claim 1, wherein R.sup.2 is --C(O)R.sup.1a, --C(O)CH(NR.sup.1bR.sup.1c)R.sup.1a, --C(O)CH[N(C(O)R.sup.1b)R.sup.1c]R.sup.1a, --C(O)CH[N(C(O)OR.sup.1b)R.sup.1c]R.sup.1a, or --C(O)CH[N(C(O)NR.sup.1dR.sup.1b)R.sup.1c]R.sup.1a. 16. The method of claim 15, wherein R.sup.2 is --C(O)CH[N(C(O)OR.sup.1b)R.sup.1c]R.sup.1a. 17. The method of claim 3, wherein each R.sup.1e is independently hydrogen or --C(O)OR.sup.1b. 18. The method of claim 1, wherein each R.sup.1a is independently hydrogen, methyl, isopropyl, 2-methylpropyl, 1-methylpropyl, 2-methylthioethyl, phenyl, benzyl, 3-indolylmethyl, hydroxymethyl, 1-hydroxyethyl, sulfhydrylmethyl, 4-hydroxybenzyl, aminocarbonylmethyl, 2-(aminocarbonyl)ethyl, carboxymethyl, 2-carboxyethyl, 4-aminobutyl, 3-guanidinopropyl, or 5-imidazolylmethyl. 19. The method of claim 1, wherein R.sup.1b is methyl, ethyl, propyl, or butyl. 20. The method of claim 1, wherein R.sup.1c is hydrogen. 21. The method of claim 1, wherein R.sup.1a and R.sup.1c together with the C and N atoms to which they are attached form pyrrolidinyl. 22. The method of claim 1, wherein each R.sup.3a is independently hydrogen, chloro, fluoro, nitro, amino, hydroxy, methyl, trifluoromethyl, cyclohexyl, phenyl, methoxy, or methoxycarbonyl. 23. The method of claim 1, wherein each R.sup.3 is independently chloro, fluoro, nitro, amino, hydroxy, methyl, trifluoromethyl, cyclohexyl, phenyl, methoxy, or methoxycarbonyl. 24. The method of claim 1, wherein n is 0. 25. The method of claim 1, wherein n is an integer of 2 or more. 26. The method of claim 25, wherein two R.sup.5 groups are linked together to form C.sub.1-6 alkylene, optionally substituted with one or more substituents Q. 27. The method of claim 25, wherein two R.sup.5 groups are linked together to form methylene or ethylene. 28. The method of claim 1, wherein q is 1 or 2. 29. The method of claim 1, wherein the moiety ##STR00406## has the structure of: ##STR00407## 30. The method of claim 1, wherein p is 0. 31. The method of claim 1, wherein p is an integer of 2 or more. 32. The method of claim 31, wherein two R.sup.6 groups are linked together to form C.sub.1-6 alkylene, optionally substituted with one or more substituents Q. 33. The method of claim 32, wherein two R.sup.6 groups are linked together to form methylene or ethylene. 34. The method of claim 1, wherein r is 1 or 2. 35. The method of claim 1, wherein the moiety ##STR00408## has the structure of: ##STR00409## 36. A method for treating an HCV infection in a human patient, which comprises administering to the human patient a compound selected from: ##STR00410## ##STR00411## ##STR00412## ##STR00413## ##STR00414## ##STR00415## ##STR00416## ##STR00417## ##STR00418## or isotopic variants thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof. 37. The method of claim 1, wherein the method comprises administering to the patient a second antiviral agent, in combination or alternation. 38. The method of claim 37, wherein the second antiviral agent is ribavirin, amantadine, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenanthrenequinone, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, acerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, or a ribozyme. 39. A method of treating, a liver disease or disorder associated with an HCV infection in a human patient, comprising administering to the patient a compound of Formula IC: ##STR00419## or a single enantiomer, a racemic mixture, a mixture of diastereomers, or a pharmaceutically acceptable salt, or solvate thereof; wherein: each R.sup.1 and R.sup.2 is independently (a) hydrogen; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) --C(O)R.sup.1a, --C(O)CH(NR.sup.1bR.sup.1c)R.sup.1a, --C(O)CH(N(R.sup.1c)C(O)R.sup.1b)R.sup.1a, --C(O)CH(N(R.sup.1c)C(O)OR.sup.1b)R.sup.1a, --C(O)CH(N(R.sup.1c)C(O)NR.sup.1bR.sup.1d)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1bR.sup.1c, --C(NR.sup.1a)NR.sup.1bR.sup.1c, --P(O)(OR.sup.1a)R.sup.1d, --CH.sub.2P(O)(OR.sup.1a)R.sup.1d, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --S(O)NR.sup.1bR.sup.1c, or --S(O).sub.2NR.sup.1bR.sup.1c; each R.sup.3a is independently hydrogen or R.sup.3; each R.sup.3, R.sup.5, and R.sup.6 is independently (a) cyano, halo, or nitro; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1bR.sup.1c, --C(NR.sup.1a)NR.sup.1bR.sup.1c, --OR.sup.1a, --OC(O)R.sup.1a, --OC(O)OR.sup.1a, --OC(O)NR.sup.1bR.sup.1c, --OC(.dbd.NR.sup.1a)NR.sup.1bR.sup.1c, --OS(O)R.sup.1a, --OS(O).sub.2R.sup.1a, --OS(O)NR.sup.1bR.sup.1c, --OS(O).sub.2NR.sup.1bR.sup.1c, --NR.sup.1bR.sup.1c, --NR.sup.1aC(O)R.sup.1d, --NR.sup.1aC(O)OR.sup.1d, --NR.sup.1aC(O)NR.sup.1bR.sup.1c, --NR.sup.1aC(.dbd.NR.sup.1d)NR.sup.1bR.sup.1c, --NR.sup.1aS(O)R.sup.1d, --NR.sup.1aS(O).sub.2R.sup.1d, --NR.sup.1aS(O)NR.sup.1bR.sup.1c, --NR.sup.1aS(O).sub.2NR.sup.1bR.sup.1c, --SR.sup.1a, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --S(O)NR.sup.1bR.sup.1c, or --S(O).sub.2NR.sup.1bR.sup.1c; or two R.sup.5 or two R.sup.6 that are attached to the same ring are linked together to form a bond, --O--, --NR.sup.7--, --S--, C.sub.1-6 alkylene, C.sub.1-6 heteroalkylene, C.sub.2-6 alkenylene, or C.sub.2-6 heteroalkenylene; L.sup.1 and L.sup.2 are each independently: a bond, ##STR00420## wherein each moiety is optionally substituted with one, two, three, or four R.sup.3; the star (*) on each moiety represents the point of attachment thought which the moiety is connected to ##STR00421## and the zigzag line () on each moiety represents the point of attachment through which the moiety is connected to ##STR00422## and wherein T.sup.3 is a bond, C, N, O, S, CR.sup.3a, or NR.sup.3a; U.sup.3, V.sup.3, W.sup.3, and X.sup.3 are each independently C, N, O, S, CR.sup.3a, or NR.sup.3a; and Y.sup.3 is C or N; each Z.sup.1 and Z.sup.2 is independently a bond; each R.sup.7 is independently (a) hydrogen; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1bR.sup.1c, --C(NR.sup.1a)NR.sup.1bR.sup.1c, --OR.sup.1a, --OC(O)R.sup.1a, --OC(O)OR.sup.1a, --OC(O)NR.sup.1bR.sup.1c, --OC(.dbd.NR.sup.1a)NR.sup.1bR.sup.1c, --OS(O)R.sup.1a, --OS(O).sub.2R.sup.1a, --OS(O)NR.sup.1bR.sup.1c, --OS(O).sub.2NR.sup.1bR.sup.1c, --NR.sup.1bR.sup.1c, --NR.sup.1aC(O)R.sup.1d, --NR.sup.1aC(O)OR.sup.1d, --NR.sup.1aC(O)NR.sup.1bR.sup.1c, --NR.sup.1aC(.dbd.NR.sup.1d)NR.sup.1bR.sup.1c, --NR.sup.1aS(O)R.sup.1d, --NR.sup.1aS(O).sub.2R.sup.1d, --NR.sup.1aS(O)NR.sup.1bR.sup.1c, --NR.sup.1aS(O).sub.2NR.sup.1bR.sup.1c, --P(O)(OR.sup.1a)R.sup.1d, CH.sub.2P(O)(OR.sup.1a)R.sup.1d, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --S(O)NR.sup.1bR.sup.1c, or --S(O).sub.2NR.sup.1bR.sup.1c; each R.sup.1a, R.sup.1b, R.sup.1c, and R.sup.1d is independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or R.sup.1a and R.sup.1c together with the C and N atoms to which they are attached form heterocyclyl; or R.sup.1b and R.sup.1c together with the N atom to which they are attached form heterocyclyl; each n and p is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7; each q and r is independently an integer of 1, 2, 3, or 4; wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more substituents Q, where each Q is independently (a) cyano, halo, or nitro; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one or more substituents Q.sup.a; and (c) --C(O)R.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.bR.sup.c, --C(NR.sup.a)NR.sup.bR.sup.c, --OR.sup.a, --OC(O)R.sup.a, --OC(O)OR.sup.a, --OC(O)NR.sup.bR.sup.c, --OC(.dbd.NR.sup.a)NR.sup.bR.sup.c, --OS(O)R.sup.a, --OS(O).sub.2R.sup.a, --OS(O)NR.sup.bR.sup.c, --OS(O).sub.2NR.sup.bR.sup.c, --NR.sup.bR.sup.c, --NR.sup.aC(O)R.sup.d, --NR.sup.aC(O)OR.sup.d, --NR.sup.aC(O)NR.sup.bR.sup.c, --NR.sup.aC(.dbd.NR.sup.d)NR.sup.bR.sup.c, --NR.sup.aS(O)R.sup.d, --NR.sup.aS(O).sub.2R.sup.d, --NR.sup.aS(O)NR.sup.bR.sup.c, --NR.sup.aS(O).sub.2NR.sup.bR.sup.c, --SR.sup.a, --S(O)R.sup.a, --S(O).sub.2R.sup.a, --S(O)NR.sup.bR.sup.c, or --S(O).sub.2NR.sup.bR.sup.c, wherein each R.sup.a, R.sup.b, R.sup.c, and R.sup.d is independently (i) hydrogen; (ii) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q.sup.a; or (iii) R.sup.b and R.sup.c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Q.sup.a; wherein each Q.sup.a is independently (a) cyano, halo, and nitro; (b) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, and heterocyclyl; or (c) --C(O)R.sup.e, --C(O)OR.sup.e, --C(O)NR.sup.fR.sup.g, --C(NR.sup.e)NR.sup.fR.sup.g, --OR.sup.e, --OC(O)R.sup.e, --OC(O)OR.sup.e, --OC(O)NR.sup.fR.sup.g, --OC(.dbd.NR.sup.e)NR.sup.fR.sup.g, --OS(O)R.sup.e, --OS(O).sub.2R.sup.e, --OS(O)NR.sup.fR.sup.g, --OS(O).sub.2NR.sup.fR.sup.g, --NR.sup.fR.sup.g, --NR.sup.eC(O)R.sup.h, --NR.sup.eC(O)OR.sup.f, --NR.sup.eC(O)NR.sup.fR.sup.g, --NR.sup.eC(.dbd.NR.sup.h)NR.sup.fR.sup.g, --NR.sup.eS(O)R.sup.h, --NR.sup.eS(O).sub.2R.sup.h, --NR.sup.eS(O)NR.sup.fR.sup.g, --NR.sup.eS(O).sub.2NR.sup.fR.sup.g, --SR.sup.e, --S(O)R.sup.e, --S(O).sub.2R.sup.e, --S(O)NR.sup.fR.sup.g, or --S(O).sub.2NR.sup.fR.sup.g; wherein each R.sup.e, R.sup.f, R.sup.g, and R.sup.h is independently (i) hydrogen; (ii) C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R.sup.f and R.sup.g together with the N atom to which they are attached form heterocyclyl. 40. The method of claim 39, wherein the method comprises administering to the paient a second antiviral agent, in combination or alternation. 41. The method of claim 40, wherein the second antiviral agent is ribavirin, amantadine, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenanthrenequinone, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, acerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, or a ribozyme. 42. A method for treating an HCV infection in a human patient, which comprises administering to the patient a compound of the structure: ##STR00423## 43. A method of treating a liver disease or disorder associated with an HCV infection in a human patient, which comprises administering to the patient a compound of the structure: ##STR00424## 44. A method for treating an HCV infection in a human patient, which comprises administering to the patient a pharmaceutically acceptable salt of: ##STR00425## 45. A method of treating a liver disease or disorder associated with an HCV infection in a human patient, which comprises administering to the patient a pharmaceutically acceptable salt of: ##STR00426##

Details for Patent 9,187,496

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2029-12-18
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2029-12-18